Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sars-cov-2 prefusion spike delta TM recombinant protein vaccine with AF03 adjuvant
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoV2 preS dTM-AF03 is a recombinant protein-based vaccine candidate developed for the prevention of COVID-19. It consists of a stabilized prefusion form of the SARS-CoV-2 spike (S) protein, produced using a baculovirus expression system in insect cells, and is formulated with the AF03 oil-in-water squalene-based adjuvant to enhance immune response. The primary mechanism is immunostimulation via induction of neutralizing antibodies against the SARS-CoV-2 S protein. The vaccine was developed by Sanofi Pasteur and has been evaluated in clinical trials for safety and immunogenicity as both primary vaccination and booster in adults[1][3][6].
- Other names
- SARS-CoV-2 prefusion spike delta TM (CoV2 preS dTM) with AF03 adjuvantsars-cov-2 pres dtm (booster only) vaccine, recombinant
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on sars-cov-2 prefusion spike delta TM recombinant protein vaccine with AF03 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sars-cov-2 prefusion spike delta TM recombinant protein vaccine with AF03 adjuvant.